ReviewFrontiers in immunology2026
Immune dysfunction in nucleotide excision repair disorders: an underrecognized clinical phenotype with relevance for inborn errors of immunity.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleotide excision repair (NER) is a conserved genome maintenance pathway that removes bulky, helix-distorting DNA lesions, including ultraviolet-induced photoproducts and chemically induced adducts. By restoring DNA integrity, NER preserves transcriptional continuity and replicative fitness, thereby limiting mutagenesis, replication stress, and cell death. Inherited defects in NER genes cause rare disorders such as xeroderma pigmentosum (XP), Cockayne syndrome (CS), and trichothiodystrophy (TTD), classically associated with photosensitivity, neurodevelopmental impairment, growth failure, and, in some subtypes, marked cancer predisposition. Traditionally, clinical attention has focused on dermatologic and neurologic manifestations, whereas immune dysfunction has been regarded as peripheral or secondary. Recent clinical and immunological studies indicate that immune abnormalities may represent an underrecognized component of selected NER disorders. Reported findings include impaired vaccine responses, hypogammaglobulinemia, IgG subclass deficiency, altered B cell differentiation, CD4 lymphopenia, restricted T cell receptor repertoires, and defective dendritic cell maturation. These abnormalities are not evenly distributed across the NER spectrum and appear more prominent in selected molecular subgroups. In particular, disorders affecting transcription-associated NER functions, including TFIIH-linked conditions, may combine impaired DNA repair with reduced transcriptional capacity, thereby increasing immune-cell vulnerability during activation. By contrast, many repair-dominant XP subtypes seem to retain largely preserved baseline immune function, although clinically relevant abnormalities may become apparent during infection, vaccination, or other immune challenges. In this Mini Review, we summarize clinical evidence for immune dysfunction in NER disorders, interpret it in the context of global genome and transcription-coupled NER, and discuss implications for immunological assessment and inborn errors of immunity-oriented classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.